SHARE
 
David R. Andes, MD close
Tvg6uXVvHQc
David R. Andes, MD
 

New Patients

Contact the Welcome Center for help choosing a new primary care doctor.

For Referring Physicians

How to refer a patient

David R. Andes, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Andes’ clinical interests include general infectious diseases, transplant infectious diseases, mycology, antimicrobial pharmacokinetics and pharmacodynamics. 

Specialties

Infectious Diseases

Travel Medicine

Clinics

University Hospital
(608) 263-0946 | (800) 323-8942 | Map
University Hospital
(608) 890-6167 | (800) 323-8942 | Map

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Infectious Diseases
Fellowship University of Wisconsin Hospital and Clinics, Madison, WI
Residency University of Wisconsin Hospital and Clinics, Madison, WI
Internship University of Wisconsin Hospital and Clinics, Madison, WI
Medical School University of Missouri School of Medicine, Columbia, MO

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.
Research

The overriding themes of our research programs are to advance our understanding of antibacterial and antifungal activity and drug resistance, and to identify new antimicrobial drug treatment strategies and drug targets.


PubMed Articles
Andes D Candidemia in the Growing Opioid Epidemic: A Distinct and Emerging Entity. Clin Infect Dis . 2020 Oct 23;71(7):1738-1740
[PubMed ID: 31676896]
Lepak AJ Wang W Andes DR Pharmacodynamic Evaluation of MRX-8, a Novel Polymyxin, in the Neutropenic Mouse Thigh and Lung Infection Models against Gram-Negative Pathogens. Antimicrob Agents Chemother . 2020 Oct 20;64(11)
[PubMed ID: 32868332]
Vanamala K Tatiparti K Bhise K Sau S Scheetz MH Rybak MJ Andes D Iyer AK Novel approaches for the treatment of methicillin-resistant Staphylococcus aureus: using nanoparticles to overcome multidrug resistance. Drug Discov Today . 2020 Oct 20;
[PubMed ID: 33091564]
McCreary EK Nguyen MH Davis MR Borlagdan J Shields RK Anderson AD Rivosecchi RM Marini RV Sacha LM Silveira FP Andes DR Lepak AJ Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube. J Antimicrob Chemother . 2020 Oct 1;75(10):3023-3028
[PubMed ID: 32710097]
Donnelly JP Chen SC Kauffman CA Steinbach WJ Baddley JW Verweij PE Clancy CJ Wingard JR Lockhart SR Groll AH Sorrell TC Bassetti M Akan H Alexander BD Andes D Azoulay E Bialek R Bradsher RW Bretagne S Calandra T Caliendo AM Castagnola E Cruciani M Cuenca-Estrella M Decker CF Desai SR Fisher B Harrison T Heussel CP Jensen HE Kibbler CC Kontoyiannis DP Kullberg BJ Lagrou K Lamoth F Lehrnbecher T Loeffler J Lortholary O Maertens J Marchetti O Marr KA Masur H Meis JF Morrisey CO Nucci M Ostrosky-Zeichner L Pagano L Patterson TF Perfect JR Racil Z Roilides E Ruhnke M Prokop CS Shoham S Slavin MA Stevens DA Thompson GR Vazquez JA Viscoli C Walsh TJ Warris A Wheat LJ White PL Zaoutis TE Pappas PG Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis . 2020 Sep 12;71(6):1367-1376
[PubMed ID: 31802125]
Johnson MD Lewis RE Dodds Ashley ES Ostrosky-Zeichner L Zaoutis T Thompson GR Andes DR Walsh TJ Pappas PG Cornely OA Perfect JR Kontoyiannis DP Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium. J Infect Dis . 2020 Aug 5;222(Supplement_3):S175-S198
[PubMed ID: 32756879]
Rodríguez López AL Lee MR Wang NB Dunn KK Sanchez H Raman N Andes DR Lynn DM Palecek SP Correction for Rodríguez López et al., "Small-Molecule Morphogenesis Modulators Enhance the Ability of 14-Helical β-Peptides To Prevent Candida albicans Biofilm Formation". Antimicrob Agents Chemother . 2020 Jun 23;64(7)
[PubMed ID: 32576596]
Thomas CS Braun DR Olmos JL Jr Rajski SR Phillips GN Jr Andes D Bugni TS Pyridine-2,6-Dithiocarboxylic Acid and Its Metal Complexes: New Inhibitors of New Delhi Metallo β-Lactamase-1. Mar Drugs . 2020 Jun 2;18(6)
[PubMed ID: 32498259]
Beredaki MI Georgiou PC Siopi M Kanioura L Andes D Arendrup MC Mouton JW Meletiadis J Toward Harmonization of Voriconazole CLSI and EUCAST Breakpoints for Candida albicans Using a Validated <i>In Vitro</i> Pharmacokinetic/Pharmacodynamic Model. Antimicrob Agents Chemother . 2020 May 21;64(6)
[PubMed ID: 32229492]
Ambrose PG Bhavnani SM Andes DR Bradley JS Flamm RK Pogue JM Jones RN Old In Vitro Antimicrobial Breakpoints Are Misleading Stewardship Efforts, Delaying Adoption of Innovative Therapies, and Harming Patients. Open Forum Infect Dis . 2020 Jul;7(7):ofaa084
[PubMed ID: 32667364]
Nett JE Andes DR Contributions of the Biofilm Matrix to <i>Candida</i> Pathogenesis. J Fungi (Basel) . 2020 Feb 3;6(1)
[PubMed ID: 32028622]
Pogue JM Jones RN Bradley JS Andes DR Bhavnani SM Drusano GL Dudley MN Flamm RK Rodvold KA Ambrose PG Polymyxin Susceptibility Testing and Interpretive Breakpoints: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST). Antimicrob Agents Chemother . 2020 Jan 27;64(2)
[PubMed ID: 31767718]
Lepak AJ Zhao M Marchillo K VanHecker J Andes DR <i>In Vivo</i> Pharmacodynamic Evaluation of Omadacycline against Staphylococcus aureus in the Neutropenic Mouse Pneumonia Model. Antimicrob Agents Chemother . 2020 Jan 27;64(2)
[PubMed ID: 31712210]
Mevers E Saurí J Helfrich EJN Henke M Barns KJ Bugni TS Andes D Currie CR Clardy J Pyonitrins A-D: Chimeric Natural Products Produced by <i>Pseudomonas protegens</i>. J Am Chem Soc . 2019 Oct 30;141(43):17098-17101
[PubMed ID: 31600443]
Lepak AJ Zhao M Andes DR Determination of Pharmacodynamic Target Exposures for Rezafungin against Candida tropicalis and Candida dubliniensis in the Neutropenic Mouse Disseminated Candidiasis Model. Antimicrob Agents Chemother . 2019 Nov;63(11)
[PubMed ID: 31481440]
Lepak AJ Zhao M Andes DR WCK 5222 (Cefepime/Zidebactam) Pharmacodynamic Target Analysis against Metallo-β-lactamase producing <i>Enterobacteriaceae</i> in the Neutropenic Mouse Pneumonia Model. Antimicrob Agents Chemother . 2019 Oct 7;
[PubMed ID: 31591114]
Jorgenson MR Descourouez JL Marka NA Leverson GE Smith JA Andes DR Fernandez LA Foley DP A targeted fungal prophylaxis protocol with static dosed fluconazole significantly reduces invasive fungal infection after liver transplantation. Transpl Infect Dis . 2019 Oct;21(5):e13156
[PubMed ID: 31390109]
Zhao M Lepak AJ Marchillo K Andes DR <i>In Vivo</i> Pharmacodynamic Target Determination for Delafloxacin against Klebsiella pneumoniae and Pseudomonas aeruginosa in the Neutropenic Murine Pneumonia Model. Antimicrob Agents Chemother . 2019 Oct;63(10)
[PubMed ID: 31332063]
McCreary EK Bayless M Van AP Lepak AJ Wiebe DA Schulz LT Andes DR Impact of Triazole Therapeutic Drug Monitoring Availability and Timing. Antimicrob Agents Chemother . 2019 Oct;63(10)
[PubMed ID: 31332058]
Rodríguez López AL Lee MR Wang NB Dunn KK Sanchez H Raman N Andes DR Lynn DM Palecek SP Small-Molecule Morphogenesis Modulators Enhance the Ability of 14-Helical β-Peptides To Prevent Candida albicans Biofilm Formation. Antimicrob Agents Chemother . 2019 Sep;63(9)
[PubMed ID: 31209011]